Volume 4.36 | Sep 20

Prostate Cell News 4.36 September 20, 2013
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
HPMA Copolymer-Based Combination Therapy Toxic to Both Prostate Cancer Stem/Progenitor Cells and Differentiated Cells Induces Durable Anti-Tumor Effects
Researchers found that, in PC-3 or RC-92a/hTERT prostate cancer cells, HPMA copolymer-cyclopamine conjugate preferentially kills and impairs the function of CD133+ prostate cancer stem/progenitor cells; HPMA copolymer-docetaxel conjugate was able to kill bulk tumor cells instead of cancer stem-like cells. [J Control Release] Abstract
Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by impact factor of the journal)

Efficient Delivery of Therapeutic Small Nucleic Acids to Prostate Cancer Cells Using Ketal Nucleoside Lipid Nanoparticles
Researchers report that Ketals Nucleoside Lipids are suitable transfecting reagents for the development of novel therapeutic approaches involving either siRNA or antisense oligonucleotide against human prostate cancer PC-3 cells resistant to chemotherapy. [J Control Release] Abstract

Androgen Receptor and MicroRNA-21 Axis Downregulates Transforming Growth Factor Beta Receptor II (TGFBR2) Expression in Prostate Cancer
Scientists showed that coordinated action of microRNA (miR)-21 and androgen receptor signaling had a critical role in inhibiting transforming growth factor β receptor II (TGFBR2) expression in prostate cancer cells. [Oncogene] Abstract

SOCS2 Mediates the Crosstalk between Androgen and Growth Hormone Signaling in Prostate Cancer
Researchers investigated the role of SOCS2 as mediator of the crosstalk between androgens and GH signals in the prostate and its potential role as tumor suppressor in prostate cancer. [Carcinogenesis] Abstract

Contextual Effect of Repression of Bone Morphogenetic Protein Activity in Prostate Cancer
Scientists used two cell lines, one isolated from a primary tumor and the other from a recurrent tumor arising at the primary site, both from the conditional Pten deletion mouse model of prostatic adenocarcinoma. Over-expression of the bone morphogenetic protein antagonist Noggin inhibited proliferation of cE1 cells in vitro while enhancing their ability to migrate. [Endocr Relat Cancer] Abstract

The Novel Toluidine Sulphonamide EL102 Shows Pre-Clinical In Vitro and In Vivo Activity against Prostate Cancer and Circumvents MDR1 Resistance
Researchers investigated the potential efficacy of EL102, a novel toluidine sulphonamide, in pre-clinical models of prostate cancer. They found that EL102 has in vitro activity against prostate cancer, characterized by accumulation in G2/M, induction of apoptosis, inhibition of Hif1α, and inhibition of tubulin polymerization and decreased microtubule stability. [Br J Cancer] Full Article

SOX2 Plays a Critical Role in EGFR-Mediated Self-Renewal of Human Prostate Cancer Stem-Like Cells
Scientists report a significant upregulation of SOX2 at both mRNA and protein levels in DU145 prostate cancer stem cells (PCSCs) propagated as suspension spheres in vitro. The expression of SOX2 in DU145 PCSCs is positively regulated by epidermal growth factor receptor (EGFR) signaling. [Cell Signal] Abstract

BMCC1 Is an AP-2 Associated Endosomal Protein in Prostate Cancer Cells
Scientists demonstrated for the first time the expression of a >300 kDa BMCC1 protein (BMCC1-1) in prostate cancer and melanoma cell lines. This protein was found exclusively in the microsomal fraction and localized to cytoplasmic vesicles. [PLoS One] Full Article

Tanshinone IIA Inhibits Human Prostate Cancer Cells Growth by Induction of Endoplasmic Reticulum Stress In Vitro and In Vivo
Investigators explored the mechanisms of cell death induced by tanshinone IIA (Tan-IIA) treatment in prostate cancer cells in vitro and in vivo. Their results showed that Tan-IIA caused prostate cancer cell death in a dose-dependent manner, and cell cycle arrest at G0/G1 phase was noted, in LNCaP cells. [Prostate Cancer P D] Abstract


Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
To identify men at greatest risk for bone metastasis or death, researchers evaluated relationships between prostate-specific antigen (PSA) and PSA doubling time (PSADT) with bone metastasis-free survival (BMFS) in a placebo group and the efficacy and safety of denosumab in men with PSADT ≤10, ≤6, and ≤4 months. In the placebo group, shorter BMFS was observed as PSADT decreased below 8 months. [J Clin Oncol] Abstract

Changes in fPSA Level Could Discriminate tPSA Flare-Up from tPSA Progression in Patients with Castration-Refractory Prostate Cancer during the Initial Phase of Docetaxel-Based Chemotherapy
Researchers evaluated whether changes in fPSA level could predict tPSA flare-up in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy. According to changes in tPSA level, 79 patients were divided into three groups: response (group 1), progression (group 2) and flare-up (group 3). fPSA and tPSA levels showed different patterns in groups 1, 2 and 3. [Cancer Chemother Pharmacol] Abstract

Detect 7 times more prostate epithelial progenitors with ProstaCult
TRAIL and MicroRNAs in the Treatment of Prostate Cancer: Therapeutic Potential and Role of Nanotechnology
The authors outline outstanding developments in therapeutic strategies based on the regulation and/or targeting of tumor necrosis factor alpha-related apoptosis-inducing ligand pathway for the treatment of prostate cancer. [Appl Microbiol Biotechnol] Abstract

Visit our REVIEWS page to see a complete list of reviews in the prostate cell research field.
New Drug that Delivers Targeted Radiation Minimizes Pain and May Extend Prostate Cancer Survival
A new treatment for advanced prostate cancer has been shown to minimize pain and extend life for prostate cancer patients with advanced disease that has spread to the bones. The targeted radiation treatment, a radiopharmaceutical drug known as Xofigo, is injected into the body to precisely deliver radiation while minimizing damage to healthy tissue. [PR Newswire Association LLC] Press Release

Dendreon Announces Marketing Authorization for PROVENGE® in the European Union
Dendreon Corporation announced that the European Commission has granted marketing authorization for PROVENGE® dispersion for infusion in the European Union for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated. [Dendreon Corporation] Press Release

Prostate Cancer Foundation and Movember Drive Scientific Discovery to Battle Prostate Cancer
The Prostate Cancer Foundation (PCF) announced that it has funded six Movember-PCF Challenge Awards that aim to accelerate scientific discovery and new treatments for prostate cancer patients. The projects chosen represent a range of focus and expertise that will tackle the most challenging problems that prostate cancer patients face in the clinic. [Business Wire] Press Release

Roche and Inovio Pharmaceuticals Partner on Inovio’s Prostate Cancer and Hepatitis B Immunotherapy Products
Roche and Inovio Pharmaceuticals, Inc. announced that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio’s highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development and have generated robust T-cell responses in animal models. [Inovio Pharmaceuticals, Inc.] Press Release

New wallchart from our sponsor: Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Best of Oncology 2013 East Conference
November 29, 3013
Toronto, Canada

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Research Associates – Tumor Immune Evasion Mechanism and Inflammation (Hollings Cancer Center)

NEW Postdoctoral Fellow – Prostate Cancer and Head & Neck Cancer (University of Maryland Baltimore)

Research Associate – Prostate Cancer (University of Virginia)

Postdoctoral Position – Prostate Molecular Biology and Cancer Biology (University of California San Francisco)

Postdoctoral Position – Prostate Cancer Biology (University Of Rochester School Of Medicine)

Postdoctoral Position – Cancer Genomics and Epigenomics (Ontario Cancer Institute / Princess Margaret Hospital)

Postdoctoral Fellow – Prostate Cancer Research (Mount Sinai School of Medicine)

Research Associate II – Anti-Cancer Agents for the Treatment of Prostate Cancer (Johnson & Johnson)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Mesenchymal Cell Research (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Quality Control Analyst – Media (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Prostate Cell News: Archives | Events | Contact Us